Estrogen and collagen are directly linked, so it's a fair question: if declining estrogen drives collagen loss, does replacing estrogen protect against it? The honest answer is more layered than either a marketing claim or a fear-based headline usually allows. Some of the research is genuinely encouraging. Some of it is decades old and limited in scope. And the decision to start hormone therapy involves far more than skin, which is exactly why the major clinical guidelines frame it the way they do.
The Original Data on Estrogen Therapy and Skin Collagen
Some of the earliest and most frequently cited research on this question came from Brincat and colleagues, who measured skin collagen content in women at different stages relative to menopause and found that collagen content correlated more closely with time since menopause, and with estrogen status, than with chronological age alone.¹ That same body of work laid the foundation for later studies examining whether restoring estrogen could influence the same collagen decline it had helped identify.
What a Systemic Hormone Therapy Study Found
A study by Sauerbronn and colleagues examined the effects of systemic hormone replacement therapy on the skin of postmenopausal women and found measurable differences in skin collagen and thickness associated with treatment, compared with women not receiving therapy.² Findings like this support the underlying mechanism, estrogen receptors on dermal fibroblasts responding to restored estrogen, but a single study, particularly an older one without the scale of a large multicenter trial, is not the same thing as settled clinical guidance.
Timing and Formulation Complicate the Picture
Estrogen and skin elasticity research consistently points to one added complication: timing matters. Collagen-related benefits observed in these studies tend to be more pronounced closer to the menopause transition, when the underlying tissue hasn't yet undergone years of unaddressed decline. This is also where collagen and perimenopause research becomes relevant to the timing question: some clinicians consider hormone therapy earlier in the transition, before the postmenopausal collagen cliff, on the theory that intervening before tissue loss compounds may preserve more structure than intervening after. Formulation matters too, since oral, transdermal, and topical estrogen don't reach skin tissue the same way, and studies differ in dose, delivery method, and duration. This is part of why the collagen findings across the literature aren't fully consistent in size, even when they point in the same general direction.
What Major Guidelines Say About Estrogen Therapy and Collagen Loss
The North American Menopause Society's 2022 position statement on hormone therapy, developed by reviewing the full body of randomized and observational evidence, supports hormone therapy as the most effective treatment for menopause symptoms and notes bone protection as an established benefit, while framing the decision around an individual woman's age, time since menopause, and personal risk factors rather than any single tissue outcome.³ Skin and collagen benefits are a plausible, evidence-supported effect of estrogen therapy. They are not, on their own, the basis on which major guideline bodies recommend starting or continuing treatment.
Population Evidence Versus Your Own Decision
This is the distinction that gets lost most often. Studies describe what happened, on average, across a group of women in a specific trial with a specific formulation and duration. They cannot tell an individual woman, with her own health history, family risk factors, and reasons for considering therapy, what the right decision is for her specifically. The estrogen and collagen relationship, the related research on estrogen and tendons, estrogen and skin elasticity, estrogen and cartilage, plus estrogen and bone remodeling, show something real biologically. Neither replaces a conversation with a clinician who knows the individual case, including personal and family history of breast cancer, cardiovascular disease, and blood clots, all of which factor into whether hormone therapy is appropriate for a given woman.
Where This Leaves the Collagen Loss Question
If you're already on hormone therapy for symptom relief, the collagen and skin elasticity research offers a reasonable secondary benefit to expect, not a guarantee. If you're not on it and considering it purely for skin or joint reasons, the evidence doesn't yet support that as a primary indication on its own, according to current guidance. Either way, collagen support doesn't have to depend on that decision. This is part of why Monna's formulas are built around bioactive collagen peptides studied independently of hormone status, VERISOL®, FORTIBONE®, and FORTIGEL®, so that structural support remains available regardless of whether you’re taking hormone therapy or not.
This article is for informational purposes and is not medical advice. Hormone therapy carries individual risks and benefits that should be discussed with a qualified clinician. Monna Super Collagen is not intended to cure or prevent any disease.